Viral dynamics of acute HIV-1 infection

Journal of Experimental Medicine

Volumn 190, Issue 6, 1999, Pages 841-850

  Little, Susan J ^a,e   McLean, Angela R ^b   Spina, Celsa A ^c,d   Richman, Douglas D ^a,c,d   Havlir, Diane V ^a,e  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Basic reproductive number; Lymphocyte dynamics; Modeling; Primary HIV; Viral decay

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; VIREMIA; VIROGENESIS; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS VACCINES; FEMALE; HIV-1; HUMANS; MALE; MIDDLE AGED; TIME FACTORS; VIREMIA; VIRUS REPLICATION;

EID: 0033588891     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.190.6.841     Document Type: Article

References (39)

1. Clark, S.J., M.S. Saag, W.D. Decker, S. Campbell-Hill, J.L. Roberson, P.J. Veldkamp, J.C. Kappes, B.H. Hahn, and G.M. Shaw. 1991. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N. Eng. J. Med. 324:954-960.
2. Daar, E.S., T. Moudgil, R.D. Meyer, and D.D. Ho. 1991. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N. Engl. J. Med. 324:961-964.
3. Cooper, D.A., J. Gold, P. Maclean, B. Donovan, R. Finlayson, T.G. Barnes, H.M. Michelmore, P. Brooke, and R. Penny. 1985. Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion. Lancet. 1:537-540.
4. Ho, D.D., M.G. Sarngadharan, L. Resnick, F. Dimarzoveronese, T.R. Rota, and M.S. Hirsch. 1985. Primary human T-lymphotropic virus type III infection. Ann. Intern. Med. 103:880-883.
5. Mellors, J.W., L.A. Kingsley, C.R.J. Rinaldo, J.A. Todd, B.S. Hoo, R.P. Kokka, and P. Gupta. 1995. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann. Intern. Med. 122:573-579.
6. O'Brien, T.R., W.A. Blattner, D. Waters, E. Eyster, M.W. Hilgartner, A.R. Cohen, N. Luban, A. Hatzakis, L.M. Aledort, P.S. Rosenberg, et al. 1996. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA. 276:105-110.
7. Macdonald, G. 1952. The analysis of equilibrium in malaria. Trop. Dis. Bull. 49:813-829.
8. McLean, A. 1996. Can HIV be eradicated from an infected individual? Antiviral Therapy 1 (Suppl.) 4-5. (Abstr.)
9. 1995. Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood - France, United Kingdom, and United States, January 1988-August 1994. MMWR Morb. Mortal. Wkly. Rep. 44: 929-933.
10. 1998. Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. Centers for Disease Control and Prevention. MMWR Morb. Mortal. Wkly. Rep. 47(RR-7):1-33.
11. Katz, M.H., and J.L. Gerberding. 1998. The care of persons with recent sexual exposure to HIV. Ann. Intern. Med. 128: 306-312.
12. Nowak, M.A., A.L. Lloyd, G.M. Vasquez, T.A. Wiltrout, L.M. Wahl, N. Bischofberger, J. Williams, A. Kinter, A.S. Fauci, V.M. Hirsch, et al. 1997. Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J. Virol. 71:7518-7525.
13. McLean, A.R., V.C. Emery, A. Webster, and P.D. Griffiths. 1991. Population dynamics of HIV within an individual after treatment with zidovudine. AIDS. 5:485-489.
14. Phillips, A.N. 1996. Reduction of HIV concentration during acute infection: independence from a specific immune response. Science. 271:497-499.
15. + lymphocytes. Science. 283:857-860.
16. Kim, S.Y., R. Byrn, J. Groopman, and D. Baltimore. 1989. Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. J. Virol. 63:3708-3713.
17. Guatelli, J.C., T.R. Gingeras, and D.D. Richman. 1990. Alternative splice acceptor utilization during human immunodeficiency virus type 1 infection of cultured cells. J. Virol. 64: 4093-4098.
18. Perelson, A.S., A.U. Neumann, M. Markowitz, J.M. Leonard, and D.D. Ho. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell lifetime, and viral generation time. Science. 271:1582-1586.
19. Schacker, T.W., J. Hughes, T. Shea, and L. Corey. 1996. Virologic course of primary HIV infection. 3rd Conference on Retroviruses and Opportunistic Infections. 480. (Abstr.)
20. + T cell responses associated with control of viremia. Science. 278:1447-1450.
21. Neumann, A.U., R. Tubiana, V. Calvez, C. Robert, T.-S. Li, H. Agut, B. Autran, and C. Katlama. 1999. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. AIDS. 13:677-683.
22. Erice, A., D.L. Mayers, D.G. Strike, K.J. Sannerud, F.E. McCutchan, K. Henry, and H.H. Balfour, Jr. 1993. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N. Engl. J. Med. 328:1163-1165.
23. Imrie, A., A. Carr, C. Duncombe, R. Finlayson, J. Vizzard, M. Law, J. Kaldor, R. Penny, and D.A. Cooper. 1996. Primary infection with zidovudine-resistant human immunodeficiency virus type 1 does not adversely affect outcome at 1 year. Sydney Primary HIV Infection Study Group. J. Infect. Dis. 174:195-198.
24. Imrie, A., A. Beveridge, W. Genn, J. Vizzard, and D.A. Cooper. 1997. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group. J. Infect. Dis. 175: 1502-1506.
25. Bonhoeffer, S., R.M. May, G.M. Shaw, and M.A. Nowak. 1997. Virus dynamics and drug therapy. Proc. Natl. Acad. Sci. USA. 94:6971-6976.
26. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5:512-517.
27. Wong, J., M. Hezareh, H. Gunthard, D.V. Havlir, C.C. Ignacio, C.A. Spina, and D.D. Richman. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 278:1291-1295.
28. Finzi, D., M. Hermankova, T. Pierson, L.M. Carruth, C. Buck, R.E. Chaisson, T.C. Quinn, K. Chadwick, J. Margolick, R. Brookmeyer, et al. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 278:1295-1300.
29. Spina, C.A., H.E. Prince, and D.D. Richman. 1997. Preferential replication of HIV-1 in the CD45RO memory cell subset of primary CD4 lymphocytes in vitro. J. Clin. Invest. 99:1774-1785.
30. McDougal, J.S., A. Mawle, S.P. Cort, J.K. Nicholson, G.D. Cross, J.A. Scheppler-Campbell, D. Hicks, and J. Sligh. 1985. Cellular tropism of the human retrovirus HTLV-III/ LAV. I. Role of T cell activation and expression of the T4 antigen. J. Immunol. 135:3151-3162.
31. + memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals. Proc. Natl. Acad. Sci. USA. 87:6058-6062.
32. Stevenson, M., T.L. Stanwick, M.P. Dempsey, and C.A. Lamonica. 1990. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO (Eur. Mol. Biol. Organ.) J. 9:1551-1560.
33. Staprans, S.I., B.L. Hamilton, S.E. Follansbee, T. Elbeik, P. Barbosa, R.M. Grant, and M.B. Feinberg. 1995. Activation of virus replication after vaccination of HIV-1-infected individuals. J. Exp. Med. 182:1727-1737.
34. Riggs, N.L., S.J. Little, D.D. Richman, and J.C. Guatelli. 1998. Cell-associated viral RNA expression during acute infection with HIV type 1. AIDS Res. Hum. Retroviruses. 14: 1141-1149.
35. Ho, D. 1998. Novel Approaches for the Evaluation of New Drugs: Approaches Using Viral Dynamics. 5th Conference on Retroviruses and Opportunistic Injections. S49. (Abstr.)
36. DeWolf, F., V. Lukashov, S. Danner, J. Goudsmit, and J. Lange. 1998. Clearance of HIV-1 Following Treatment with Three, Four and Five Anti-HIV Drugs. 5th Conference on Retroviruses and Opportunistic Injections. 384. (Abstr.)
37. Notermans, D.W., J. Goudsmit, S.A. Danner, F. de Wolf, A.S. Perelson, and J. Mittler. 1998. Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen. AIDS. 12:1483-1490.
38. McLean, A. 1998. CTL Effectiveness In Vivo. 5th Annual HIV Dynamics and Evolution Conference. 31. (Abstr.)
39. Mellors, J.W., C.R. Rinaldo, Jr., P. Gupta, R.M. White, J.A. Todd, and L.A. Kingsley. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 272:1167-1170.